Acorda Therapeutics (DB:CDG) - Cours de l'action, nouvelles et analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CDG Aperçu des actions

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Plus de détails

CDG analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	3/6
Dividendes	0/6

Récompenses

Les revenus ont augmenté 10.3% par an au cours des 5 dernières années

Analyse des risques

Les actions sont très illiquides

N'a pas de capitalisation boursière significative ( €15M )

Les actionnaires ont été dilués au cours de l'année écoulée

Acorda Therapeutics, Inc. Concurrents

Medigene

XTRA:MDG1

€22.6m

co.don

XTRA:CNW

€6.5m

Paion

XTRA:PA8

€2.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Acorda Therapeutics
Historique des cours de bourse
Prix actuel de l'action	US$8.42
Plus haut sur 52 semaines	US$21.80
Plus bas sur 52 semaines	US$5.64
Bêta	1.43
1Variation sur 1 mois	0%
Variation sur 3 mois	-6.83%
Variation sur 1 an	10.25%
3Variation sur 3 ans	-83.90%
Variation sur 5 ans	-99.70%
Évolution depuis l'introduction en bourse	-98.76%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	CDG	DE Biotechs	DE Marché
7D	0%	-0.7%	-0.02%
1Y	10.2%	-17.2%	8.2%

Rendement vs Industrie: CDG a dépassé le secteur German Biotechs qui a rapporté -17.2 % au cours de l'année écoulée.

Rendement vs marché: CDG a dépassé le marché German qui a rapporté 8.2 % au cours de l'année écoulée.

Volatilité des prix

Is CDG's price volatile compared to industry and market?
CDG volatility
CDG Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: Le cours de l'action de CDG a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de CDG au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1995	111	Ron Cohen	www.acorda.com

Acorda Therapeutics, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Acorda Therapeutics se comparent-ils à sa capitalisation boursière ?
CDG statistiques fondamentales
Capitalisation boursière	€14.12m
Bénéfices(TTM)	-€19.42m
Recettes(TTM)	€108.53m

0.1x

Ratio P/S

-0.7x

Ratio P/E

Le site CDG est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
CDG compte de résultat (TTM)
Recettes	US$116.91m
Coût des recettes	US$27.38m
Marge brute	US$89.53m
Autres dépenses	US$110.45m
Les revenus	-US$20.92m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-16.84
Marge brute	76.58%
Marge bénéficiaire nette	-17.89%
Ratio dettes/capitaux propres	259.6%

Quelles ont été les performances à long terme de CDG?

Voir les performances historiques et les comparaisons

This company listing is no longer active

CDG Aperçu des actions

Récompenses

Analyse des risques

Acorda Therapeutics, Inc. Concurrents

XTRA:MDG1

€22.6m

XTRA:CNW

€6.5m

XTRA:PA8

€2.6m

XTRA:HPHA

€103.9m

Historique des prix et performances

Nouvelles et mises à jour récentes

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Motion for Joint Administration Filed by Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Revenue beats expectations

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.

New 90-day high: €5.42

Third quarter 2020 earnings released: EPS US$0.15

Revenue beats expectations

New 90-day high: €0.89

Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, Inc

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index

New 90-day low - €0.40